Important note
This AI stock analysis for Astrazeneca is not up to date. Creating and accessing our AI stock Analysis (powered by our data and Chat GPT) is only available for our premium users. Sign up to get access today!
Astrazeneca - AI Stock Analysis
Analysis generated November 27, 2024
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company operates in various therapeutic areas, including oncology, cardiovascular, renal & metabolism, respiratory, and immunology. AstraZeneca has a strong presence in over 100 countries, and its innovative medicines are used by millions of patients worldwide.
Fundamental Analysis
Revenue: The revenue for the last quarter was $13.6 billion. This marks a 4.85% growth compared to the previous quarter, which is a positive sign of growth. Compared to the same quarter last year, there is an increase of 18.04%, showing robust year-over-year growth.
Net Income: The net income for the last quarter was $1.43 billion. While this represents a decrease of 25.84% compared to the previous quarter, which could be a concern, compared to the same quarter last year, there is a 4.00% growth, indicating positive year-over-year performance.
EBITDA: The EBITDA for the last quarter was $4.1 billion. This represents a slight decrease of 0.41% compared to the previous quarter. However, compared to the same quarter last year, there is a significant increase of 22.92%, again showing strong year-over-year growth.
P/E Ratio: The current P/E ratio is 31.92. This is considered high, indicating a potential overvaluation of the stock and possibly a bearish outlook.
Technical Analysis
Stock Price: Today's stock price is $67.20, reflecting a decrease of 10.46% compared to a month ago, which may be concerning in the short term. However, compared to a year ago, there is an increase of 8.46%, showcasing a positive long-term trend.
Trend: The trend is currently bullish.
SMA10: The current SMA10 is $65.15, which is higher than the previous SMA10 of $64.75. This indicates a potential upward trend in price movement.
RSI: The RSI is 58.1, indicating a neutral condition.
Alternative Data Analysis
Job Postings and Employee Sentiment: AstraZeneca has 1,105 open positions, with stability over the last couple of months, indicating a stable company. 82% of employees have a positive outlook, another positive sign.
Customer Acquisition: AstraZeneca has an estimated 960,000 visitors to their webpage, with an increase of 21% in the last couple of months. This indicates a bullish trend as it can suggest an increase in customers.
Customer Engagement: AstraZeneca has 78,000 followers on their Instagram page, with a 4% increase in the past few months, indicating increased interest. However, the company has 300,000 followers on Twitter, with a 1% decrease in followers, which might indicate a slight dip in interest.
AI Score: According to AltIndex's AI score, AstraZeneca has a score of 72, which is a buy signal.
Conclusion and Recommendation
Based on the provided data, AstraZeneca presents a mixed yet promising outlook. The company's financials depict strong year-over-year growth in revenue and EBITDA, although the quarter-over-quarter decreases in net income and EBITDA raise some concerns. With a high P/E ratio, there is a potential overvaluation to consider.
From a technical perspective, the stock is in a bullish trend with long-term positive movement despite short-term fluctuations. The stable job postings, high employee sentiment, and increasing web traffic highlight a positive business environment. Finally, the AI score of 72 provides a buy signal based on a comprehensive analysis.
Considering all these factors, AstraZeneca is recommended as a stock to watch with a positive outlook. Potential investors should keep an eye on quarterly performance and valuation metrics while capitalizing on long-term growth trends.
Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.
